[HTML][HTML] Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges
MV Dhodapkar - Frontiers in bioscience: a journal and virtual …, 2009 - ncbi.nlm.nih.gov
MV Dhodapkar
Frontiers in bioscience: a journal and virtual library, 2009•ncbi.nlm.nih.govGlycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population
of T cells implicated in the regulation of immune responses in a broad range of diseases
including cancer. Several studies have demonstrated the capacity of NKT cells bearing an
invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity
and mediate tumor rejection in mice. Early phase clinical studies in humans have
demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo …
of T cells implicated in the regulation of immune responses in a broad range of diseases
including cancer. Several studies have demonstrated the capacity of NKT cells bearing an
invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity
and mediate tumor rejection in mice. Early phase clinical studies in humans have
demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo …
Abstract
Glycolipid reactive CD1d restricted natural killer T (NKT) cells represent a distinct population of T cells implicated in the regulation of immune responses in a broad range of diseases including cancer. Several studies have demonstrated the capacity of NKT cells bearing an invariant T cell receptor (iNKT cells) to recruit both innate and adaptive anti-tumor immunity and mediate tumor rejection in mice. Early phase clinical studies in humans have demonstrated the capacity of dendritic cells (DCs) to mediate expansion of NKT cells in vivo. However several challenges need to be overcome in order to effectively harness the properties of these cells in the clinic.
ncbi.nlm.nih.gov